Introduction: InWAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-Up Stroke), patients with an acute stroke of unknown onset time were randomized to treatment with intravenous alteplase or placebo, guided by MRI. Methods: In this exploratory post-hoc secondary analysis we compared clinical and imaging data, as well as treatment effects and safety of intravenous thrombolysis between patients with infra- vs. supratentorial stroke. Results: Forty-eight out of 503 randomized patients (9.5%) presented with a stroke involving the cerebellum or brainstem. Patients with infratentorial stroke were younger compared to patients with supratentorial stroke (mean age 60 vs. 66 years), more frequently male (85 vs. 62%), and less sev...
Background: Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advance...
Background Stroke thrombolysis with alteplase is currently recommended 0-4.5 h after stroke onset. W...
Background and Purpose—We assessed whether lower-dose alteplase at 0.6 mg/kg is efficacious and safe...
Introduction: In WAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-Up Stroke), patien...
Introduction: In WAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-Up Stroke), patients...
Background: Patients who have had a stroke with unknown time of onset have been previously exclude...
Background: Under current guidelines, intravenous thrombolysis is used to treat acute stroke only i...
Importance: The rationale for intravenous thrombolysis in patients with lacunar infarcts is debated,...
Background: One quarter to one third of patients eligible for systemic thrombolysis are on antipla...
Background and Objectives: Cerebral microbleeds (CMBs) are common in acute ischemic stroke patients ...
Importance: The rationale for intravenous thrombolysis in patients with lacunar infarcts is debated,...
Background: The “smoking paradox” indicates that patients with acute ischemic stroke (AIS) who smoke...
Background: The "smoking paradox" indicates that patients with acute ischemic stroke (AIS) who smoke...
BACKGROUND: Under current guidelines, intravenous thrombolysis is used to treat acute stroke only if...
Background: Patients who have had a stroke with unknown time of onset have been previously excluded ...
Background: Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advance...
Background Stroke thrombolysis with alteplase is currently recommended 0-4.5 h after stroke onset. W...
Background and Purpose—We assessed whether lower-dose alteplase at 0.6 mg/kg is efficacious and safe...
Introduction: In WAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-Up Stroke), patien...
Introduction: In WAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-Up Stroke), patients...
Background: Patients who have had a stroke with unknown time of onset have been previously exclude...
Background: Under current guidelines, intravenous thrombolysis is used to treat acute stroke only i...
Importance: The rationale for intravenous thrombolysis in patients with lacunar infarcts is debated,...
Background: One quarter to one third of patients eligible for systemic thrombolysis are on antipla...
Background and Objectives: Cerebral microbleeds (CMBs) are common in acute ischemic stroke patients ...
Importance: The rationale for intravenous thrombolysis in patients with lacunar infarcts is debated,...
Background: The “smoking paradox” indicates that patients with acute ischemic stroke (AIS) who smoke...
Background: The "smoking paradox" indicates that patients with acute ischemic stroke (AIS) who smoke...
BACKGROUND: Under current guidelines, intravenous thrombolysis is used to treat acute stroke only if...
Background: Patients who have had a stroke with unknown time of onset have been previously excluded ...
Background: Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advance...
Background Stroke thrombolysis with alteplase is currently recommended 0-4.5 h after stroke onset. W...
Background and Purpose—We assessed whether lower-dose alteplase at 0.6 mg/kg is efficacious and safe...